Jung Wook Kang Smith, MD
Family Medicine · Evansville, INNPI 1770842460
Payments from drug & device makers
Across 433 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$1K
- Novo Nordisk$607
- Pfizer$507
- GSK$481
- Vanda Pharmaceuticals Inc.$389
- plus $3K from 30 others
What the payments were for
- Food & beverage$7,124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,309 |
| AstraZeneca | 34 | $1,041 |
| Novo Nordisk | 45 | $607 |
| Pfizer | 30 | $507 |
| GSK | 28 | $481 |
| Vanda Pharmaceuticals Inc. | 18 | $389 |
| Amgen(2 entities) | 25 | $363 |
| Lilly USA, LLC | 25 | $343 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $317 |
| Boehringer Ingelheim | 22 | $309 |
| Merck | 20 | $299 |
| Axsome Therapeutics, Inc. | 9 | $169 |
| Otsuka America Pharmaceutical, Inc. | 7 | $127 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $76 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $74 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Exact Sciences | 4 | $59 |
| Bayer | 3 | $55 |
| Corium, LLC | 4 | $53 |
| Dexcom, Inc. | 3 | $48 |
| Astellas Pharma US Inc | 2 | $45 |
| Novartis | 3 | $43 |
| Scilex Pharmaceuticals Inc. | 1 | $41 |
| Lundbeck LLC | 2 | $35 |
| Ironshore Pharmaceuticals Inc. | 1 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $19 |
| Tris Pharma Inc | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,124 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $164,898 |
| JardianceEmpagliflozin | 145 | $143,942 |
| FarxigaDapagliflozin Propanediol | 59 | $61,867 |
| RexultiBrexpiprazole | 22 | $48,513 |
| TrulicityDulaglutide | 27 | $47,443 |
| VraylarCariprazine Hcl | 24 | $35,222 |
| EliquisApixaban | 26 | $30,883 |
| Spiriva RespimatTiotropium Bromide | 34 | $25,822 |
| MounjaroTirzepatide | 21 | $25,323 |
| Repatha SureclickEvolocumab | 16 | $24,956 |
| JanuviaSitagliptin Phosphate | 15 | $22,470 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,312 |
| LinzessLinaclotide | 17 | $18,754 |
| XareltoRivaroxaban | 12 | $15,996 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $12,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $309 | $169,764179 claims |
| Novo NordiskOzempic | $607 | $164,898143 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $343 | $72,76648 claims |
| AstraZenecaFarxiga, Symbicort | $1,041 | $68,61577 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,309 | $55,15555 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $127 | $48,51322 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $481 | $34,66250 claims |
| PfizerEliquis | $507 | $30,88326 claims |
| MerckJanuvia | $299 | $22,47015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Evansville
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Alexander Dela LlanaEvansville$1.6M
- David BrougherEvansville$556K
- Anthony InzerelloEvansville$338K
- James GutmannEvansville$311K
- Randall StoltzEvansville$248K
- William SmithEvansville$150K
- Carol GoodmanEvansville$123K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.